Randomised placebo controlled trials in HIV infection: to be or not to be?

di Gelmon, K, Weller, I V
Pubblicazione 1989

Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art

di Clemons, M., Gelmon, K.A., Pritchard, K.I., Paterson, A.H.G.
Pubblicazione 2012

Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience

di Baxter, E., Gondara, L., Lohrisch, C., Chia, S., Gelmon, K., Hayes, M., Davidson, A., Tyldesley, S.
Pubblicato in Curr Oncol (2015)

Endocrine therapy for postmenopausal women with hormone receptor–positive her2–negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor t...

di Pritchard, K.I., Gelmon, K.A., Rayson, D., Provencher, L., Webster, M., McLeod, D., Verma, S.
Pubblicazione 2013

Outcomes of women with early-stage breast cancer receiving adjuvant trastuzumab

di Seal, M.D., Speers, C.H., O’Reilly, S., Gelmon, K.A., Ellard, S.L., Chia, S.K.
Pubblicazione 2012

Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer

di Bebb, D G, Yu, Z, Chen, J, Telatar, M, Gelmon, K, Phillips, N, Gatti, R A, Glickman, B W
Pubblicazione 1999

Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1

di Kalra, J, Sutherland, B W, Stratford, A L, Dragowska, W, Gelmon, K A, Dedhar, S, Dunn, S E, Bally, M B
Pubblicazione 2010

Neoadjuvant therapy for breast cancer: updates and proceedings from the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer

di Arnaout, A., Lee, J., Gelmon, K., Poirier, B., Lu, F.I., Akra, M., Boileau, J.F., Tonkin, K., Li, H., Illman, C., Simmons, C., Grenier, D.
Pubblicato in Curr Oncol (2018)

The sequential use of endocrine treatment for advanced breast cancer: where are we?

di Barrios, C., Forbes, J. F., Jonat, W., Conte, P., Gradishar, W., Buzdar, A., Gelmon, K., Gnant, M., Bonneterre, J., Toi, M., Hudis, C., Robertson, J. F. R.
Pubblicato in Ann Oncol (2012)

TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial

di Bartlett, J M S, Nielsen, T O, Gao, D, Gelmon, K A, Quintayo, M A, Starczynski, J, Han, L, Burnell, M J, Levine, M N, Chen, B E, Shepherd, L E, Chapman, J W
Pubblicato in Br J Cancer (2015)

Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy

di Courneya, K S, McKenzie, D C, Mackey, J R, Gelmon, K, Friedenreich, C M, Yasui, Y, Reid, R D, Vallerand, J R, Adams, S C, Proulx, C, Dolan, L B, Wooding, E, Segal, R J
Pubblicato in Br J Cancer (2014)

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

di Rugo, H S, Diéras, V, Gelmon, K A, Finn, R S, Slamon, D J, Martin, M, Neven, P, Shparyk, Y, Mori, A, Lu, D R, Bhattacharyya, H, Bartlett, C Huang, Iyer, S, Johnston, S, Ettl, J, Harbeck, N
Pubblicato in Ann Oncol (2018)

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

di Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., Mori, A., Gauthier, E. R., Bartlett, C. Huang, Gelmon, K. A., Slamon, D. J.
Pubblicato in Breast Cancer Res Treat (2019)

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

di Turner, N C, Finn, R S, Martin, M, Im, S -A, DeMichele, A, Ettl, J, Diéras, V, Moulder, S, Lipatov, O, Colleoni, M, Cristofanilli, M, Lu, D R, Mori, A, Giorgetti, C, Iyer, S, Bartlett, C Huang, Gelmon, K A
Pubblicato in Ann Oncol (2018)

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

di Dawson, S-J, Makretsov, N, Blows, F M, Driver, K E, Provenzano, E, Le Quesne, J, Baglietto, L, Severi, G, Giles, G G, McLean, C A, Callagy, G, Green, A R, Ellis, I, Gelmon, K, Turashvili, G, Leung, S, Aparicio, S, Huntsman, D, Caldas, C, Pharoah, P
Pubblicazione 2010

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

di Dawson, S-J, Makretsov, N, Blows, F M, Driver, K E, Provenzano, E, Le Quesne, J, Baglietto, L, Severi, G, Giles, G G, McLean, C A, Callagy, G, Green, A R, Ellis, I, Gelmon, K, Turashvili, G, Leung, S, Aparicio, S, Huntsman, D, Caldas, C, Pharoah, P
Pubblicazione 2010

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

di Goss, P.E., Ingle, J.N., Pritchard, K.I., Robert, N.J., Muss, H., Gralow, J., Gelmon, K., Whelan, T., Strasser-Weippl, K., Rubin, S., Sturtz, K., Wolff, A.C., Winer, E., Hudis, C., Stopeck, A., Beck, J.T., Kaur, J.S., Whelan, K., Tu, D., Parulekar, W.R.
Pubblicato in N Engl J Med (2016)

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

di Yerushalmi, R., Dong, B., Chapman, J. W., Goss, P. E., Pollak, M. N., Burnell, M. J., Levine, M. N., Bramwell, V. H. C., Pritchard, K. I., Whelan, T. J., Ingle, J. N., Shepherd, L. E., Parulekar, W. R., Han, L., Ding, K., Gelmon, K. A.
Pubblicato in Ann Oncol (2017)

PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2

di Wishart, G C, Bajdik, C D, Dicks, E, Provenzano, E, Schmidt, M K, Sherman, M, Greenberg, D C, Green, A R, Gelmon, K A, Kosma, V-M, Olson, J E, Beckmann, M W, Winqvist, R, Cross, S S, Severi, G, Huntsman, D, Pylkäs, K, Ellis, I, Nielsen, T O, Giles, G, Blomqvist, C, Fasching, P A, Couch, F J, Rakha, E, Foulkes, W D, Blows, F M, Bégin, L R, van't Veer, L J, Southey, M, Nevanlinna, H, Mannermaa, A, Cox, A, Cheang, M, Baglietto, L, Caldas, C, Garcia-Closas, M, Pharoah, P D P
Pubblicazione 2012

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)(†)

di Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., Cardoso, M. J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S. H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U. N., Mayer, M., Merjaver, S. D., Nordström, E. B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M. J., Rugo, H., Sledge, G., Thomssen, C., van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., Winer, E.
Pubblicazione 2014